Abstract
In blood coagulation, thrombin helps to activate factor XIII by cleaving the activation peptide at the R37−G38 peptide bond. The more easily activated factor XIII V34L has been correlated with protection from myocardial infarction. V34L and V29F factor XIII mutant peptides were designed to further characterize substrate binding to thrombin. HPLC kinetic studies have been carried out on thrombin hydrolysis of FXIII activation peptide (28−41), FXIII (28−41) V34L, FXIII (28−41) V29F, and FXIII (28−41) V29F V34L. The V34L mutations lead to improvements in both Km and kcat whereas the V29F mutation primarily affects Km. Interactions of the peptides with thrombin have been monitored by 1D proton line broadening NMR and 2D transferred NOESY studies. The results were compared with previously published X-ray crystal structures of thrombin-bound fibrinogen Aα (7−16), thrombin receptor PAR1 (38−60), and factor XIII (28−37). In solution, the 34VVPR37 and 34LVPR37 segments of the factor XIII activation peptide serve as the major anchor points onto thrombin. The N-terminal segments are proposed to interact transiently with the enzyme surface. Long-range NOEs from FXIII V29 or F29 toward 34V/LVPR37 have not been observed by NMR studies. Overall, the kinetic and NMR results suggest that the factor XIII activation peptide binds to thrombin in a manner more similar to the thrombin receptor PAR1 than to fibrinogen Aα. The V29 and V34 positions affect, in different ways, the ability of thrombin to effectively hydrolyze the activation peptide. Mutations at these sites may prove useful in controlling factor XIII activation.